<DOC>
	<DOCNO>NCT03095118</DOCNO>
	<brief_summary>This study do see daratumumab safe effective treatment proliferative glomerulonephritis monoclonal immune deposit ( PGNMID ) C3 glomerulopathy associate monoclonal gammopathy ( C3GN ) . This inflammatory disease kidney due production abnormal protein . There know standard effective treatment patient PGNMID C3GN secondary monoclonal gammopathy . These disease cause abnormal production protein ( monoclonal ) abnormal clone . Daratumamb show effective treating patient multiple myeloma disease also cause production monoclonal protein abnormal clone . Everyone study receive daratumumab .</brief_summary>
	<brief_title>Daratumumab Treatment PGNIMD C3 GN</brief_title>
	<detailed_description>This study open-label phase 2 trial safety efficacy daratumumab , treatment PGNMID C3GN associate monoclonal gammopathy . Subjects screen outpatient Nephrology Clinic visit appointment interested qualified subject consent offered participation trial . Once consent obtain baseline value establish subject begin treatment follow-up next 12 month . Daratumumab administer weekly 8 week every 2 week 8 additional dos . Patients follow total 12 month ( 6 month last infusion ) . A final visit evaluation collection lab sample conduct end study .</detailed_description>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Glomerulonephritis , Membranoproliferative</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age ≥ 18 year age Renal biopsy read Mayo Clinic confirm diagnosis PGNMID C3 GN In case C3GN serum electrophoresis immunofixation confirm presence monoclonal gammopathy Proteinuria ≥ 1000 mg 24 hour eGFR ≥ 20 mL/min/SA Subjects able willing give inform consent Pregnancy Hepatitis B C , HIV Multiple myeloma Anemia Hgb &lt; 8.5 g/dL Thrombocytopenia platelet count &lt; 100,000 Leukopenia WBC &lt; 3.5 Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Unable provide consent Patients receive therapy oral prednisone glucocorticoid equivalent last 6 week Patients receive immunosuppressive therapy include cyclophosphamide , MMF , cyclosporine , tacrolimus azathioprine last 3 month Patients receive rituximab previously CD20 count zero time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>